Skip to main content

Questions about COVID-19 and your benefits?  Learn more here

Drug Plan Trends Report: A snapshot of what’s coming down the pike

Share this post

Medavie Blue Cross has also seen a significant decline in new patient starts for hepatitis C medications, says Chris Goguen, the insurer’s strategic pharmaceutical partnerships lead in Moncton, N.B. Demand is now one-fifth of the volume it was a year-and-a-half ago, although there may be a slight bump if and when the medications are approved for more indications, says Christine Than, a pharmacist and drug solutions specialist at Aon Hewitt in Montreal.

Click here to read the full article

Chris Goguen

Chris joined Medavie Blue Cross in 2015, with 25 years of experience as a senior leader within the...